Ashraf, J. M.,Ansari, M. A.,Fatma, S.,Abdullah, S. M. S.,Iqbal, J.,Madkhali, A.,Hamali, A. H.,Ahmad, S.,Jerah, A.,Echeverria, V.,Barreto, G. E.,Ashraf, G. M.

2018

September

Mol Neurobiolmol Neurobiol

Inhibiting Effect of Zinc Oxide Nanoparticles on Advanced Glycation Products and Oxidative Modifications: a Potential Tool to Counteract Oxidative Stress in Neurodegenerative Diseases

Published

()

Aloe/chemistry Glycation End Products, Advanced/*metabolism Humans Nanoparticles/*chemistry/ultrastructure Neurodegenerative Diseases/*pathology Oxidation-Reduction Oxidative Stress/*drug effects Plant Extracts/chemistry Plant Leaves/chemistry Spectrometry, Fluorescence Spectrophotometry, Ultraviolet X-Ray Diffraction Zinc Oxide/*pharmacology

55

99

7438

7452

Advanced glycation end products (AGEs) are implicated in several central nervous system (CNS) pathologies including Alzheimer and Parkinson's diseases. In the face-off of AGE menace, we have attempted to investigate the zinc oxide nanoparticle (ZnONP) role in inhibition of AGE formation. Synthesized ZnONPs were used to investigate the inhibitory effects on AGE formation. The inhibitory effects of ZnONPs on AGE formation were determined by biophysical immunological and biochemical techniques. The results showed that ZnONP is a potential anti-glycating agent inhibiting AGE formation as well as protecting the protein structure from change. Therefore, our findings suggest ZnONPs may be used as a therapeutic in resolving the AGE role in CNS-related complications.Advanced glycation end products (AGEs) are implicated in several central nervous system (CNS) pathologies including Alzheimer and Parkinson's diseases. In the face-off of AGE menace, we have attempted to investigate the zinc oxide nanoparticle (ZnONP) role in inhibition of AGE formation. Synthesized ZnONPs were used to investigate the inhibitory effects on AGE formation. The inhibitory effects of ZnONPs on AGE formation were determined by biophysical immunological and biochemical techniques. The results showed that ZnONP is a potential anti-glycating agent inhibiting AGE formation as well as protecting the protein structure from change. Therefore, our findings suggest ZnONPs may be used as a therapeutic in resolving the AGE role in CNS-related complications.

1559-1182 (Electronic) 08

2018/02/10

http://www.ncbi.nlm.nih.gov/pubmed/29423819http://www.ncbi.nlm.nih.gov/pubmed/29423819

10.1007/s12035-018-0935-x